Andrew Cittadine - 04 Mar 2025 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Operating Officer
Signature
/s/ Quan Vu, Attorney-in-fact
Issuer symbol
MNPR
Transactions as of
04 Mar 2025
Net transactions value
$0
Form type
4
Filing time
07 Mar 2025, 21:09:50 UTC
Previous filing
02 Jan 2025
Next filing
02 Apr 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Stock Options Award $0 +43,445 $0.000000 43,445 04 Mar 2025 Common Stock 43,445 $31.70 Direct F1
transaction MNPR Restricted Stock Units Award $0 +40,581 +366% $0.000000 51,655 04 Mar 2025 Common Stock 40,581 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Options Vests 6/48ths on June 30, 2025, and 1/48th per month thereafter.
F2 RSUs vest 6/48ths on June 30, 2025, and 3/48ths per quarter thereafter.